SCHEMBL23673056

SCHEMBL23673056

COCCNC(=O)c1cc(Cc2ccc(-c3cncs3)cc2)c2sccc2n1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ADORA2B P29275 5/20 0.45
▸ ADORA2A P29274 3/20 0.45
▸ CD38 P28907 3/20 0.44
▸ RAB9A P51151 3/20 0.42
▸ HPGD P15428 3/20 0.42
▸ LMNA P02545 1/20 0.42
▸ TP53 P04637 3/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ IRAK4 Q9NWZ3 1/20 0.38
▸ ADORA3 P0DMS8 1/20 0.38
▸ CSNK2A1 P68400 1/20 0.36
▸ KLKB1 P03952 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23672718 0.95 CD38 (0.44) ADORA2BADORA2ACD38RAB9AHPGD
SCHEMBL23672809 0.89 POLB (0.43) ADORA2BADORA2ACD38RAB9AHPGD
SCHEMBL23672929 0.85 ADORA2A (0.43) ADORA2BADORA2ARAB9AHPGDLMNA
SCHEMBL23672848 0.81 CD38 (0.41) ADORA2BADORA2ACD38
SCHEMBL23672827 0.80 CD38 (0.41) ADORA2BADORA2ACD38
SCHEMBL23672733 0.80 ADORA2A (0.46) ADORA2BADORA2ACD38
SCHEMBL23672756 0.80 CD38 (0.41) ADORA2BADORA2ACD38
SCHEMBL23672948 0.80 HPGDS (0.42) ADORA2BADORA2ARAB9ALMNANPC1
SCHEMBL23672634 0.80 CHRM1 (0.48) ADORA2BADORA2ACD38
SCHEMBL23673124 0.79 CHRM1 (0.44) CD38

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11111251-B2 Positive allosteric modulators of the muscarinic acetylcholine receptor M1 VANDERBILT UNIVERSITY (US) 2021-09-07 — — US claimed
US-20210230180-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 VANDERBILT UNIVERSITY 2021-07-29 — — US claimed
EP-3416639-B1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 UNIV VANDERBILT (US) 2022-06-08 — — EP disclosed
US-11111251-B2 Positive allosteric modulators of the muscarinic acetylcholine receptor M1 VANDERBILT UNIVERSITY (US) 2021-09-07 — — US disclosed
US-20210230180-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 VANDERBILT UNIVERSITY 2021-07-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210230180-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 CHRM1, CHRM2, CHRM4 ADORA2B 228/4885ADORA2A 62/4885CD38 1821/4885
US-11111251-B2 Positive allosteric modulators of the muscarinic acetylcholine receptor M1 CHRM1, CHRM2, CHRM4 ADORA2B 228/4885ADORA2A 62/4885CD38 1821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback